Identification of a proteomic signature for predicting immunotherapy response in patients with metastatic non-small cell lung cancer
-
Published:2024-08
Issue:
Volume:
Page:100834
-
ISSN:1535-9476
-
Container-title:Molecular & Cellular Proteomics
-
language:en
-
Short-container-title:Molecular & Cellular Proteomics
Author:
Mondelo-Macía PatriciaORCID,
García-González Jorge,
León-Mateos LuisORCID,
Abalo Alicia,
Bravo SusanaORCID,
Chantada Vazquez María del PilarORCID,
Muinelo-Romay Laura,
López-López Rafael,
Díaz-Peña RobertoORCID,
Dávila-Ibáñez Ana B.ORCID
Reference58 articles.
1. Delivery technologies for cancer immunotherapy;Riley;Nat Rev Drug Discov.,2019
2. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance;Bagchi;Annu Rev Pathol Mech Dis,2021
3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer;Reck;N Engl J Med,2016
4. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC;Spigel;Ann Oncol,2019
5. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial;Sezer;Lancet (London, England),2021